Key statistics
On Friday, Exelixis Inc (EX9:DUS) closed at 37.10, -13.52% below its 52-week high of 42.90, set on May 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 35.21 |
|---|---|
| High | 37.10 |
| Low | 35.21 |
| Bid | 36.65 |
| Offer | 37.32 |
| Previous close | 36.16 |
| Average volume | 5.40 |
|---|---|
| Shares outstanding | 268.11m |
| Free float | 261.87m |
| P/E (TTM) | 17.84 |
| Market cap | 11.36bn USD |
| EPS (TTM) | 2.38 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 18:31 GMT.
More ▼
Press releases
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
- Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
- Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
- Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
- Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
More ▼
